arframe TFL Gallery
  • Getting Started
    • Installation

  • Tables
    • Study Conduct
    • Enrollment by Country and Site

    • Study Population
    • Demographics Summary
    • Medical History
    • Prior Medication
    • Disposition Summary
    • Analysis Populations

    • Extent of Exposure
    • Concomitant Medications
    • Extent of Exposure

    • Safety
    • Adverse Events by System Organ Class and Preferred Term
    • AEs Related to Study Drug
    • Common Adverse Events
    • Adverse Events by Grade / Intensity
    • Overall Safety Summary
    • Adverse Events with Event Counts
    • Exposure-Adjusted Adverse Events
    • Adverse Events by Subgroup
    • Serious Adverse Events by SOC and PT
    • AEs Leading to Study Drug Discontinuation
    • Death Summary
    • Vital Signs
    • Laboratory Results - Chemistry
    • Laboratory Shift Table
    • Laboratory Worst Toxicity Grade
    • Laboratory Marked Abnormalities
    • Electrocardiogram Summary

    • Efficacy
    • Time to Event Summary
    • Best Overall Response

  • Listings
    • Adverse Event Listing
    • Demographic Characteristics Listing
    • Medical History Listing
    • Vital Signs Listing
    • Laboratory Test Results Listing
    • Concomitant Medications Listing

  • Figures
    • Kaplan-Meier Plot
    • Swimmer Plot
    • Waterfall Plot

On this page

  • arframe TFL Gallery
  • Tables
  • Figures
  • Listings

arframe TFL Gallery

Submission-ready clinical trial tables and listings. Every example runs — pick a tab, copy the code.

Tables

TABLE · STUDY POPULATION

Demographics Summary

Continuous + categorical statistics by treatment arm with Total column. Age, age group, sex, race, ethnicity. Group headers, blank-after, decimal alignment.

decimal cards

TABLE · STUDY POPULATION

Medical History

Medical history by SOC and preferred term. Hierarchical layout with indentation.

hierarchy cards

TABLE · STUDY POPULATION

Prior Medication

Prior medications by medication class and preferred name. Hierarchical layout.

hierarchy cards

TABLE · STUDY POPULATION

Subject Disposition

Screening, randomization, treatment completion, and reasons for discontinuation.

decimal cards

TABLE · STUDY POPULATION

Disposition - Screening

Screened, screen failures, and enrolled subject counts.

decimal

TABLE · STUDY POPULATION

Disposition - End of Study

End of study status — completed, discontinued, ongoing.

decimal

TABLE · STUDY CONDUCT

Enrollment by Country and Site

Enrollment counts by country with site-level detail. Hierarchical layout.

hierarchy decimal

TABLE · STUDY POPULATION

Analysis Populations

Summary of analysis populations — enrolled, safety, ITT/FAS.

decimal

TABLE · SAFETY

Death Summary

Deaths by treatment arm with cause-of-death breakdown.

decimal

TABLE · SAFETY

AE by SOC and Preferred Term

Hierarchical SOC/PT structure. Bold SOC rows, indented PTs, frequency sorting.

hierarchy decimal cards

TABLE · SAFETY

AEs Related to Study Drug

Treatment-emergent AEs related to study drug (possible/probable) by SOC and PT.

hierarchy cards

TABLE · SAFETY

Common Adverse Events

Preferred terms occurring at ≥5% in any treatment arm. Sorted by frequency.

decimal cards

TABLE · SAFETY

AE by Grade/Intensity

Adverse events by maximum CTCAE grade per treatment arm.

hierarchy decimal

TABLE · SAFETY

Overall Safety Summary

Any TEAE, SAEs, deaths, discontinuations due to AE.

decimal

TABLE · SAFETY

AE with Event Counts

SOC/PT table showing both subject counts and event counts per term.

hierarchy decimal cards

TABLE · SAFETY

Exposure-Adjusted Adverse Events

AE incidence rates per 100 patient-years by SOC and preferred term.

hierarchy decimal

TABLE · SAFETY

Adverse Events by Subgroup

Treatment-emergent AE summary stratified by treatment arm and age subgroup.

decimal split

TABLE · SAFETY

Serious AEs by SOC and PT

Serious adverse events by system organ class and preferred term. Hierarchical with bold SOC rows.

hierarchy cards

TABLE · SAFETY

AEs Leading to Discontinuation

Treatment-emergent AEs leading to study drug discontinuation by SOC and PT.

hierarchy cards

TABLE · SAFETY

Vital Signs

One row per treatment group at each visit, Value and Change from Baseline statistics as columns. Page-by parameter with spanning headers.

page_by decimal split

TABLE · EXTENT OF EXPOSURE

Concomitant Medications

Medications by ATC class and preferred name. Hierarchical with bold category rows.

hierarchy decimal

TABLE · EXTENT OF EXPOSURE

Extent of Exposure

Study drug exposure: total duration, total dose, average daily dose with duration categories.

decimal cards

TABLE · SAFETY

Laboratory Results - Chemistry

Chemistry panel summary by visit. Per-variable decimal precision showcase with fr_wide_ard().

decimal page_by cards

TABLE · SAFETY

Laboratory Marked Abnormalities

Subjects with notable high/low laboratory values by chemistry parameter and treatment arm.

decimal cards

TABLE · SAFETY

Electrocardiogram Summary

Worst post-baseline QTc categories and maximum increase from baseline by treatment arm.

decimal cards

TABLE · EFFICACY

Time to Event Summary

Overall survival with KM median, quartiles, hazard ratio, and log-rank p-value.

decimal

TABLE · EFFICACY

Best Overall Response

BOR categories with derived ORR and DCR rates. Oncology efficacy endpoint summary.

decimal cards

Figures

FIGURE · EFFICACY

Kaplan-Meier Plot

Progression-free survival curves by treatment arm with number-at-risk table.

FIGURE · EFFICACY

Swimmer Plot

Subject treatment duration with response markers over time.

FIGURE · EFFICACY

Waterfall Plot

Best percentage change from baseline in target lesion size per subject.

Listings

LISTING · SAFETY

Adverse Event Listing

Subject-level AE listing with SOC, PT, severity, onset, duration, outcome, relationship.

listing

LISTING · STUDY POPULATION

Demographic Characteristics

Subject-level demographics — age, sex, race, ethnicity, weight, height.

listing

LISTING · SAFETY

Medical History Listing

Subject-level medical history with SOC, preferred term, reported term, category, and severity.

listing page_by

LISTING · SAFETY

Vital Signs Listing

Subject-level vital signs by visit with baseline and change values.

listing page_by

LISTING · SAFETY

Laboratory Test Results Listing

Subject-level chemistry lab results with value, baseline, change, and normal range flag.

listing decimal page_by

LISTING · EXTENT OF EXPOSURE

Concomitant Medications Listing

Subject-level concomitant medications with ATC class, dose, route, and dates.

listing page_by

Source Code
---
title: ""
execute:
  echo: false
  eval: false
---

::: {.gallery-header}

# arframe TFL Gallery

Submission-ready clinical trial tables and listings. Every example runs — pick a tab, copy the code.

:::

## Tables

::: {.tlg-grid}

::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}

### [Demographics Summary](tables/demographic.qmd)

[Continuous + categorical statistics by treatment arm with Total column. Age, age group, sex, race, ethnicity. Group headers, blank-after, decimal alignment.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}

### [Medical History](tables/medical-history.qmd)

[Medical history by SOC and preferred term. Hierarchical layout with indentation.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}

### [Prior Medication](tables/prior-medication.qmd)

[Prior medications by medication class and preferred name. Hierarchical layout.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}

### [Subject Disposition](tables/disposition.qmd)

[Screening, randomization, treatment completion, and reasons for discontinuation.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}

### [Disposition - Screening](tables/disposition-screening.qmd)

[Screened, screen failures, and enrolled subject counts.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::

::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}

### [Disposition - End of Study](tables/disposition-eos.qmd)

[End of study status — completed, discontinued, ongoing.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::

::: {.tlg-card}
[TABLE · STUDY CONDUCT]{.card-type}

### [Enrollment by Country and Site](tables/enrollment-country.qmd)

[Enrollment counts by country with site-level detail. Hierarchical layout.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
:::
:::

::: {.tlg-card}
[TABLE · STUDY POPULATION]{.card-type}

### [Analysis Populations](tables/analysis-populations.qmd)

[Summary of analysis populations — enrolled, safety, ITT/FAS.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [Death Summary](tables/death-summary.qmd)

[Deaths by treatment arm with cause-of-death breakdown.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [AE by SOC and Preferred Term](tables/ae-soc-pt.qmd)

[Hierarchical SOC/PT structure. Bold SOC rows, indented PTs, frequency sorting.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [AEs Related to Study Drug](tables/ae-related.qmd)

[Treatment-emergent AEs related to study drug (possible/probable) by SOC and PT.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [Common Adverse Events](tables/ae-common.qmd)

[Preferred terms occurring at ≥5% in any treatment arm. Sorted by frequency.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [AE by Grade/Intensity](tables/ae-grade.qmd)

[Adverse events by maximum CTCAE grade per treatment arm.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [Overall Safety Summary](tables/ae-overall.qmd)

[Any TEAE, SAEs, deaths, discontinuations due to AE.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [AE with Event Counts](tables/ae-event-counts.qmd)

[SOC/PT table showing both subject counts and event counts per term.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [Exposure-Adjusted Adverse Events](tables/ae-exposure-adjusted.qmd)

[AE incidence rates per 100 patient-years by SOC and preferred term.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [Adverse Events by Subgroup](tables/ae-subgroup.qmd)

[Treatment-emergent AE summary stratified by treatment arm and age subgroup.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
[split]{.tag .tag-split}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [Serious AEs by SOC and PT](tables/ae-sae-soc-pt.qmd)

[Serious adverse events by system organ class and preferred term. Hierarchical with bold SOC rows.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [AEs Leading to Discontinuation](tables/ae-discontinuation.qmd)

[Treatment-emergent AEs leading to study drug discontinuation by SOC and PT.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [Vital Signs](tables/vitals.qmd)

[One row per treatment group at each visit, Value and Change from Baseline statistics as columns. Page-by parameter with spanning headers.]{.card-desc}

::: {.card-tags}
[page_by]{.tag .tag-pageby}
[decimal]{.tag .tag-decimal}
[split]{.tag .tag-split}
:::
:::

::: {.tlg-card}
[TABLE · EXTENT OF EXPOSURE]{.card-type}

### [Concomitant Medications](tables/conmeds.qmd)

[Medications by ATC class and preferred name. Hierarchical with bold category rows.]{.card-desc}

::: {.card-tags}
[hierarchy]{.tag .tag-hierarchy}
[decimal]{.tag .tag-decimal}
:::
:::

::: {.tlg-card}
[TABLE · EXTENT OF EXPOSURE]{.card-type}

### [Extent of Exposure](tables/exposure.qmd)

[Study drug exposure: total duration, total dose, average daily dose with duration categories.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [Laboratory Results - Chemistry](tables/lab-chemistry.qmd)

[Chemistry panel summary by visit. Per-variable decimal precision showcase with `fr_wide_ard()`.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
[page_by]{.tag .tag-pageby}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [Laboratory Marked Abnormalities](tables/lab-abnormalities.qmd)

[Subjects with notable high/low laboratory values by chemistry parameter and treatment arm.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · SAFETY]{.card-type}

### [Electrocardiogram Summary](tables/ecg-summary.qmd)

[Worst post-baseline QTc categories and maximum increase from baseline by treatment arm.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::

::: {.tlg-card}
[TABLE · EFFICACY]{.card-type}

### [Time to Event Summary](tables/tte-summary.qmd)

[Overall survival with KM median, quartiles, hazard ratio, and log-rank p-value.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
:::
:::

::: {.tlg-card}
[TABLE · EFFICACY]{.card-type}

### [Best Overall Response](tables/efficacy-bor.qmd)

[BOR categories with derived ORR and DCR rates. Oncology efficacy endpoint summary.]{.card-desc}

::: {.card-tags}
[decimal]{.tag .tag-decimal}
[cards]{.tag .tag-cards}
:::
:::

:::


## Figures

::: {.tlg-grid}

::: {.tlg-card}
[FIGURE · EFFICACY]{.card-type}

### [Kaplan-Meier Plot](figures/km-plot.qmd)

[Progression-free survival curves by treatment arm with number-at-risk table.]{.card-desc}

::: {.card-tags}
:::
:::

::: {.tlg-card}
[FIGURE · EFFICACY]{.card-type}

### [Swimmer Plot](figures/swimmer-plot.qmd)

[Subject treatment duration with response markers over time.]{.card-desc}

::: {.card-tags}
:::
:::

::: {.tlg-card}
[FIGURE · EFFICACY]{.card-type}

### [Waterfall Plot](figures/waterfall-plot.qmd)

[Best percentage change from baseline in target lesion size per subject.]{.card-desc}

::: {.card-tags}
:::
:::

:::


## Listings

::: {.tlg-grid}

::: {.tlg-card}
[LISTING · SAFETY]{.card-type}

### [Adverse Event Listing](listings/ae-listing.qmd)

[Subject-level AE listing with SOC, PT, severity, onset, duration, outcome, relationship.]{.card-desc}

::: {.card-tags}
[listing]{.tag .tag-listing}
:::
:::

::: {.tlg-card}
[LISTING · STUDY POPULATION]{.card-type}

### [Demographic Characteristics](listings/demog-listing.qmd)

[Subject-level demographics — age, sex, race, ethnicity, weight, height.]{.card-desc}

::: {.card-tags}
[listing]{.tag .tag-listing}
:::
:::

::: {.tlg-card}
[LISTING · SAFETY]{.card-type}

### [Medical History Listing](listings/mh-listing.qmd)

[Subject-level medical history with SOC, preferred term, reported term, category, and severity.]{.card-desc}

::: {.card-tags}
[listing]{.tag .tag-listing}
[page_by]{.tag .tag-pageby}
:::
:::

::: {.tlg-card}
[LISTING · SAFETY]{.card-type}

### [Vital Signs Listing](listings/vs-listing.qmd)

[Subject-level vital signs by visit with baseline and change values.]{.card-desc}

::: {.card-tags}
[listing]{.tag .tag-listing}
[page_by]{.tag .tag-pageby}
:::
:::

::: {.tlg-card}
[LISTING · SAFETY]{.card-type}

### [Laboratory Test Results Listing](listings/lab-listing.qmd)

[Subject-level chemistry lab results with value, baseline, change, and normal range flag.]{.card-desc}

::: {.card-tags}
[listing]{.tag .tag-listing}
[decimal]{.tag .tag-decimal}
[page_by]{.tag .tag-pageby}
:::
:::

::: {.tlg-card}
[LISTING · EXTENT OF EXPOSURE]{.card-type}

### [Concomitant Medications Listing](listings/conmeds.qmd)

[Subject-level concomitant medications with ATC class, dose, route, and dates.]{.card-desc}

::: {.card-tags}
[listing]{.tag .tag-listing}
[page_by]{.tag .tag-pageby}
:::
:::

:::

Open-source TFL reference collection

 

CDISC Pilot Study (CDISCPILOT01) • pharmaverseadam datasets